# Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

> **NCT01568294** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** pomalidomide

## Key facts

- **NCT ID:** NCT01568294
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-01
- **Primary completion:** 2015-07-08
- **Final completion:** 2015-07-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568294, "Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01568294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*